Car T Cells in Solid Tumors: Overcoming Obstacles
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | |
| dc.contributor.author | Rojas-Quintero, Joselyn Joanna | |
| dc.contributor.author | Diaz, Maria del Pilar | |
| dc.contributor.author | Palmar, Jim | |
| dc.contributor.author | Galan, Nataly | |
| dc.contributor.author | Morillo, Valery | |
| dc.contributor.author | Escalona, Daniel | |
| dc.contributor.author | González-Torres, Henry Joseth | |
| dc.contributor.author | Torres, Wheeler | |
| dc.contributor.author | Navarro Quiroz, Elkin | |
| dc.contributor.author | Rivera-Porras, Diego | |
| dc.contributor.author | Bermudez, Valmore | |
| dc.date.accessioned | 2025-02-04T15:43:13Z | |
| dc.date.available | 2025-02-04T15:43:13Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | Chimeric antigen receptor T cell (CAR T cell) therapy has emerged as a prominent adoptive cell therapy and a therapeutic approach of great interest in the fight against cancer. This approach has shown notorious efficacy in refractory hematological neoplasm, which has bolstered its exploration in the field of solid cancers. However, successfully managing solid tumors presents considerable intrinsic challenges, which include the necessity of guiding the modified cells toward the tumoral region, assuring their penetration and survival in adverse microenvironments, and addressing the complexity of identifying the specific antigens for each type of cancer. This review focuses on outlining the challenges faced by CAR T cell therapy when used in the treatment of solid tumors, as well as presenting optimizations and emergent approaches directed at improving its efficacy in this particular context. From precise localization to the modulation of the tumoral microenvironment and the adaptation of antigen recognition strategies, diverse pathways will be examined to overcome the current limitations and buttress the therapeutic potential of CAR T cells in the fight against solid tumors. | eng |
| dc.format.mimetype | ||
| dc.identifier.citation | Rojas-Quintero, J.; Díaz, M.P.; Palmar, J.; Galan-Freyle, N.J.; Morillo, V.; Escalona, D.; González-Torres, H.J.; Torres, W.; Navarro-Quiroz, E.; Rivera-Porras, D.; et al. Car T Cells in Solid Tumors: Overcoming Obstacles. Int. J. Mol. Sci. 2024, 25, 4170. https://doi.org/ 10.3390/ijms25084170 | eng |
| dc.identifier.doi | https://doi.org/10.3390/ijms25084170 | |
| dc.identifier.issn | 14220067 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/16206 | |
| dc.language.iso | eng | |
| dc.publisher | MDPI | spa |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | |
| dc.source | International Journal of Molecular Sciences | eng |
| dc.source | Vol. 25, Issue 8 (2024) | |
| dc.subject.keywords | Cancer | eng |
| dc.subject.keywords | Immunotherapy | eng |
| dc.subject.keywords | Solid tumors | eng |
| dc.title | Car T Cells in Solid Tumors: Overcoming Obstacles | spa |
| dc.type.driver | info:eu-repo/semantics/article | eng |
| dc.type.spa | Artículo científico | |
| dcterms.references | Almåsbak, H.; Aarvak, T.; Vemuri, M.C. CAR T Cell Therapy: A Game Changer in Cancer Treatment. J. Immunol. Res. 2016, 2016, 5474602. | eng |
| dcterms.references | Palucka, A.K.; Coussens, L.M. The Basis of Oncoimmunology. Cell 2016, 164, 1233–1247. | eng |
| dcterms.references | Chu, F.; Cao, J.; Neelalpu, S.S. Versatile CAR T-cells for cancer immunotherapy. Wspolczesna Onkol. 2018, 2018, 73–80. | eng |
| dcterms.references | Gomez, S.; Tabernacki, T.; Kobyra, J.; Roberts, P.; Chiappinelli, K.B. Combining epigenetic and immune therapy to overcome cancer resistance. Semin. Cancer Biol. 2020, 65, 99–113. | eng |
| dcterms.references | Cheng, J.; Zhao, L.; Zhang, Y.; Qin, Y.; Guan, Y.; Zhang, T.; Liu, C.; Zhou, J. Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies. Front. Oncol. 2019, 9, 1237. | eng |
| dcterms.references | Chraa, D.; Naim, A.; Olive, D.; Badou, A. T lymphocyte subsets in cancer immunity: Friends or foes. J. Leukoc. Biol. 2019, 105, 243–255. | eng |
| dcterms.references | Gross, G.; Waks, T.; Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity (chimeric genes/antibody variable region). Immunology 1989, 86, 10024–10028. | eng |
| dcterms.references | Kalaitsidou, M.; Kueberuwa, G.; Schütt, A.; Gilham, D.E. CAR T-cell therapy: Toxicity and the relevance of preclinical models. Immunotherapy 2015, 7, 487–497. | eng |
| dcterms.references | Davila, M.L.; Sauter, C.; Brentjens, R. CD19-Targeted T Cells for Hematologic Malignancies Clinical Experience to Date. Cancer J. 2015, 21, 470–474 | eng |
| dcterms.references | Zhang, J.; Medeiros, L.J.; Young, K.H. Cancer immunotherapy in diffuse large B-cell lymphoma. Front. Oncol. 2018, 8, 351. | eng |
| dcterms.references | Bagley, S.J.; O’Rourke, D.M. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions. Pharmacol. Ther. 2020, 205, 107419. | eng |
| dcterms.references | Mata, M.; Gottschalk, S. Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors. Drugs 2019, 79, 401–415. | eng |
| dcterms.references | Hu, J.; Sun, C.; Bernatchez, C.; Xia, X.; Hwu, P.; Dotti, G.; Li, S. T-cell homing therapy for reducing regulatory T cells and preserving effector T-cell function in large solid tumors. Clin. Cancer Res. 2018, 24, 2920–2934. | eng |
| dcterms.references | Rosenberg, S.A.; Packard, B.S.; Aebersold, P.M.; Solomon, D.; Topalian, S.L.; Toy, S.T.; Simon, P.; Lotze, M.T.; Yang, J.C.; Seipp, C.A.; et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 1988, 319, 1676–1680. | eng |
| dcterms.references | Forsberg, M.H.; Das, A.; Saha, K.; Capitini, C.M. The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL. Ther. Clin. Risk Manag. 2018, 14, 1573–1584. | eng |
| dcterms.references | Zolov, S.N.; Rietberg, S.P.; Bonifant, C.L. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cells. Cytotherapy 2018, 20, 1259–1266. | eng |
| dcterms.references | Barrett, D.M.; Singh, N.; Porter, D.L.; Grupp, S.A.; June, C.H. Chimeric antigen receptor therapy for cancer. Annu. Rev. Med. 2014, 65, 333–347. | eng |
| dcterms.references | Fesnak, A.D.; June, C.H.; Levine, B.L. Engineered T cells: The promise and challenges of cancer immunotherapy. Nat. Rev. Cancer 2016, 16, 566–581. | eng |
| dcterms.references | Rosewell Shaw, A.; Suzuki, M. Oncolytic Viruses Partner with T-Cell Therapy for Solid Tumor Treatment. Front. Immunol. 2018, 9, 2103. | eng |
| dcterms.references | Esmaeilzadeh, A.; Tahmasebi, S.; Athari, S.S. Chimeric antigen receptor -T cell therapy: Applications and challenges in treatment of allergy and asthma. Biomed. Pharmacother. 2020, 123, 109685. | eng |
| dcterms.references | Abate-Daga, D.; Davila, M.L. CAR models: Next-generation CAR modifications for enhanced T-cell function. Mol. Ther.-Oncolytics 2016, 3, 16014. | eng |
| dcterms.references | Kakarla, S.; Gottschalk, S. CAR T Cells for Solid Tumors Armed and Ready to Go? Cancer J. 2014, 20, 151–155. | eng |
| dcterms.references | Roselli, E.; Frieling, J.S.; Thorner, K.; Ramello, M.C.; Lynch, C.C.; Abate-Daga, D. CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms. BioDrugs 2019, 33, 647–659. | eng |
| dcterms.references | Holzinger, A.; Abken, H. CAR T Cells: A Snapshot on the Growing Options to Design a CAR. HemaSphere 2019, 3, e172. | eng |
| dcterms.references | Seif, M.; Einsele, H.; Löffler, J. CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases. Front. Immunol. 2019, 10, 2711. | eng |
| dcterms.references | Zhong, Q.; Zhu, Y.M.; Zheng, L.L.; Shen, H.J.; Ou, R.M.; Liu, Z.; She, Y.L.; Chen, R.; Li, C.; Huang, J.; et al. Chimeric antigen receptor-T Cells with 4-1BB co-stimulatory domain present a superior treatment outcome than those with CD28 domain based on bioinformatics. Acta Haematol. 2018, 140, 131–140. | eng |
| dcterms.references | Velasquez, M.P.; Szoor, A.; Vaidya, A.; Thakkar, A.; Nguyen, P.; Wu, M.F.; Liu, H.; Gottschalk, S. CD28 and 41BB costimulation enhances the effector function of CD19-specific engager T cells. Cancer Immunol Res. 2017, 5, 860–870. | eng |
| dcterms.references | Srivastava, S.; Riddell, S.R. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy. J. Immunol. 2018, 200, 459–468 | eng |
| dcterms.references | Haddadi, M.H.; Hajizadeh-Saffar, E.; Khosravi-Maharlooei, M.; Basiri, M.; Negahdari, B.; Baharvand, H. Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential. Blood Rev. 2020, 41, 100645. | eng |
| dcterms.references | Chmielewski, M.; Hombach, A.A.; Abken, H. Of CARs and TRUCKs: Chimeric Antigen Receptor (CAR) T Cells Engineered with an Inducible Cytokine to Modulate the Tumor Stroma. 2013. Available online: www.immunologicalreviews.com (accessed on 12 March 2024). | eng |
| dcterms.references | Chmielewski, M.; Abken, H. TRUCKs: The fourth generation of CARs. Expert Opin. Biol. Ther. 2015, 15, 1145–1154. | eng |
| dcterms.references | Yu, S.; Li, A.; Liu, Q.; Li, T.; Yuan, X.; Han, X.; Wu, K. Chimeric antigen receptor T cells: A novel therapy for solid tumors. J. Hematol. Oncol. 2017, 10, 1–13. | eng |
| dcterms.references | Picanco-Castro, V.; Gonçalves Pereira, C.; Swiech, K.; Ribeiro Malmegrim, K.C.; Tadeu Covas, D.; Silveira Porto, G. Emerging CAR T cell therapies: Clinical landscape and patent technological routes. Hum. Vaccines Immunother. 2020, 16, 1424–1433. | eng |
| dcterms.references | Mullard, A. FDA approves first CAR T therapy. Nat. Rev. Drug Discov. 2017, 16, 669. | eng |
| dcterms.references | FDA. Approves Second CAR T-cell Therapy. Cancer Discov. 2018, 8, 5–6. | eng |
| dcterms.references | Dudley, C.V.; Baer, B.; Simons, R.M. Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults. Semin. Oncol. Nurs. 2019, 35, 150930. | eng |
| dcterms.references | Hampton, T. Exploring the Potential of CAR-T Therapy for Heart Failure. JAMA 2019, 322, 2066–2067. | eng |
| dcterms.references | Feucht, J.; Sun, J.; Eyquem, J.; Ho, Y.J.; Zhao, Z.; Leibold, J.; Dobrin, A.; Cabriolu, A.; Hamieh, M.; Sadelain, M. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med. 2019, 25, 82–88. | eng |
| dcterms.references | FDA. YESCARTA.; Kite Pharma Inc.: Los Angeles, CA, USA, 2022. | eng |
| dcterms.references | Awasthi, R.; Maier, H.J.; Zhang, J.; Lim, S. Kymriah® (tisagenlecleucel)—An overview of the clinical development journey of the first approved CAR-T therapy. Hum. Vaccin. Immunother. 2023, 19, 2210046. | eng |
| dcterms.references | Plastaras, J.P.; Chong, E.A.; Schuster, S.J. Don’t Get Stuck on the Shoulder: Radiation Oncologists Should Get Into the CAR With T-Cell Therapies. Int. J. Radiat. Oncol. Biol. Phys. 2019, 105, 1022–1024. | eng |
| dcterms.references | Voskoboinik, I.; Whisstock, J.C.; Trapani, J.A. Perforin and granzymes: Function, dysfunction and human pathology. Nat. Rev. Immunol. 2015, 15, 388–400. | eng |
| dcterms.references | Osińska, I.; Popko, K.; Demkow, U. Perforin: An important player in immune response. Cent. Eur. J. Immunol. 2014, 39, 109–115. | eng |
| dcterms.references | Yolcu, E.S.; Shirwan, H.; Askenasy, N. Fas/fas-ligand interaction as a mechanism of immune homeostasis and β-cell cytotoxicity: Enforcement rather than neutralization for treatment of type 1 diabetes. Front. Immunol. 2017, 8, 342. | eng |
| dcterms.references | Shatursky, O.; Heuck, A.P.; Shepard, L.A.; Rossjohn, J.; Parker, M.W.; Johnson, A.E.; Tweten, R.K. The Mechanism of Membrane Insertion for a Cholesterol-Dependent Cytolysin: A Novel Paradigm for Pore-Forming Toxins large pores, and in every case, the cytolytic activity of CDCs requires the presence of cholesterol in mem-branes. Current views of cytolytic pore-forming toxins and their soluble and membrane structures are dominated. Cell 1999, 99, 293–299. | eng |
| dcterms.references | Jindal, V.; Arora, E.; Gupta, S. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors. Med. Oncol. 2018, 35, 87. | eng |
| dcterms.references | Dugnani, E.; Pasquale, V.; Bordignon, C.; Canu, A.; Piemonti, L.; Monti, P. Integrating T cell metabolism in cancer immunotherapy. Cancer Lett. 2017, 411, 12–18. | eng |
| dcterms.references | Mirzaei, H.R.; Rodriguez, A.; Shepphird, J.; Brown, C.E.; Badie, B. Chimeric antigen receptors T cell therapy in solid tumor: Challenges and clinical applications. Front. Immunol. 2017, 8, 1850. | eng |
| dcterms.references | Castellarin, M.; Watanabe, K.; June, C.H.; Kloss, C.C.; Posey, A.D. Driving cars to the clinic for solid tumors. Gene Ther. 2018, 25, 165–175. | eng |
| dcterms.references | Fowler. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial. Nature 2021, 28, 325–332. | eng |
| dcterms.references | Mueller, K.T.; Waldron, E.; Grupp, S.A.; Levine, J.E.; Laetsch, T.W.; Pulsipher, M.A.; Boyer, M.W.; August, K.J.; Hamilton, J.; Awasthi, R.; et al. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. Clin. Cancer Res. 2018, 24, 6175–6184. | eng |
| dcterms.references | Maude, S.L.; Laetsch, T.W.; Buechner, J.; Rives, S.; Boyer, M.; Bittencourt, H.; Bader, P.; Verneris, M.R.; Stefanski, H.E.; Myers, G.D.; et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med. 2018, 378, 439–448. | eng |
| dcterms.references | Maude, S.L.; Teachey, D.T.; Rheingold, S.R.; Shaw, P.A.; Aplenc, R.; Barrett, D.M.; Barker, C.S.; Callahan, C.; Frey, N.V.; Nazimuddin, F.; et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. J. Clin. Oncol. 2016, 34, 3011. | eng |
| dcterms.references | Neelapu, S.S. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023, 141, 2307–2315. | eng |
| dcterms.references | Abramson, J.S.; Palomba, M.L.; Gordon, L.I.; Lunning, M.A.; Wang, M.; Arnason, J.; Mehta, A.; Purev, E.; Maloney, D.G.; Andreadis, C.; et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet 2020, 839–852. | eng |
| dcterms.references | Mount, C.W.; Majzner, R.G.; Sundaresh, S.; Arnold, E.P.; Kadapakkam, M.; Haile, S.; Labanieh, L.; Hulleman, E.; Woo, P.J.; Rietberg, S.P.; et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas letter. Nat. Med. 2018, 24, 572–579. | eng |
| dcterms.references | Lamers, C.H.J.; Klaver, Y.; Gratama, J.W.; Sleijfer, S.; Debets, R. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells—A completed study overview. Biochem. Soc. Trans. 2016, 44, 951–959. | eng |
| dcterms.references | Kershaw, M.H.; Westwood, J.A.; Parker, L.L.; Wang, G.; Eshhar, Z.; Mavroukakis, S.A.; White, D.E.; Wunderlich, J.R.; Canevari, S.; Rogers-Freezer, L.; et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 2006, 12, 6106–6115. | eng |
| dcterms.references | Junghans, R.P.; Ma, Q.; Rathore, R.; Gomes, E.M.; Bais, A.J.; Lo, A.S.; Abedi, M.; Davies, R.A.; Cabral, H.J.; Al-Homsi, A.S.; et al. Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response. Prostate 2016, 76, 1257–1270. | eng |
| dcterms.references | Kawakami, Y.; Nishimura, M.I.; Restifo, N.P.; Topalian, S.L.; O’Neil, B.H.; Shilyansky, J.; Yannelli, J.R.; Rosenberg, S.A. T-Cell Recognition of Human Melanoma Antigens. J. Immunother. 1993, 14, 88–93. | eng |
| dcterms.references | Revisiting the hallmarks of cancer. Am. J. Cancer Res. 2017, 7, 1016. | eng |
| dcterms.references | Whilding, L.M.; Maher, J. CAR T-cell immunotherapy: The path from the by-road to the freeway? Mol. Oncol. 2015, 9, 1994–2018. | eng |
| dcterms.references | Park, J.H.; Geyer, M.B.; Brentjens, R.J. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date. Blood 2016, 127, 3312–3320. | eng |
| dcterms.references | Zhang, Q.; Ping, J.; Huang, Z.; Zhang, X.; Zhou, J.; Wang, G.; Liu, S.; Ma, J. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead. J. Immunol. Res. 2020, 2020, 1924379. | eng |
| dcterms.references | Nahas, G.R.; Komanduri, K.V.; Pereira, D.; Goodman, M.; Jimenez, A.M.; Beitinjaneh, A.; Wang, T.P.; Lekakis, L.J. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma. 2020, 61, 940–943. | eng |
| dcterms.references | Fischer, J.; Paret, C.; El Malki, K.; Alt, F.; Wingerter, A.; Neu, M.A.; Kron, B.; Russo, A.; Lehmann, N.; Roth, L.; et al. CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis. J. Immunother. 2017, 40, 187–195. | eng |
| dcterms.references | Jahn, L.; Hagedoorn, R.S.; van der Steen, D.M.; Hombrink, P.; Kester, M.G.; Schoonakker, M.P.; de Ridder, D.; van Veelen, P.A.; Falkenburg, J.F.; Heemskerk, M.H. A CD22-Reactive TCR from the T-Cell Allorepertoire for the Treatment of Acute Lymphoblastic Leukemia by TCR Gene Transfer. Oncotarget 2016, 7, 71536. | eng |
| dcterms.references | Ramos, C.A.; Ballard, B.; Zhang, H.; Dakhova, O.; Gee, A.P.; Mei, Z.; Bilgi, M.; Wu, M.F.; Liu, H.; Grilley, B.; et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J. Clin. Investig. 2017, 127, 3462–3471. | eng |
| dcterms.references | Watanabe, K.; Kuramitsu, S.; Posey, A.D.; June, C.H. Expanding the therapeutic window for CAR T cell therapy in solid tumors: The knowns and unknowns of CAR T cell biology. Front. Immunol. 2018, 9, 2486. | eng |
| dcterms.references | Long, K.B.; Young, R.M.; Boesteanu, A.C.; Davis, M.M.; Lacey, S.F.; Fraietta, J.A. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. Front. Immunol. 2018, 9, 2740. | eng |
| dcterms.references | Kailayangiri, S.; Altvater, B.; Wiebel, M.; Jamitzky, S.; Rossig, C. Overcoming heterogeneity of antigen expression for effective car t cell targeting of cancers. Cancers 2020, 12, 1075. [ | eng |
| dcterms.references | Sigismund, S.; Avanzato, D.; Lanzetti, L. Emerging functions of the EGFR in cancer. Mol. Oncol. 2018, 12, 3–20. | eng |
| dcterms.references | Sasada, T.; Azuma, K.; Ohtake, J.; Fujimoto, Y. Immune responses to epidermal growth factor receptor (EGFR) and their application for cancer treatment. Front. Pharmacol. 2016, 7, 405. | eng |
| dcterms.references | Feng, K.; Guo, Y.; Dai, H.; Wang, Y.; Li, X.; Jia, H.; Han, W. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci. China Life Sci. 2016, 59, 468–479. | eng |
| dcterms.references | Cappell, K.M.; Kochenderfer, J.N. Long-term outcomes following CAR T cell therapy: What we know so far. Nat. Rev. Clin. Oncol. 2023, 20, 359–371 | eng |
| dcterms.references | Morgan, R.A.; Yang, J.C.; Kitano, M.; Dudley, M.E.; Laurencot, C.M.; Rosenberg, S.A. Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 2010, 18, 843–851. | eng |
| dcterms.references | Iqbal, N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol. Biol. Int. 2014, 2014, 852748. | eng |
| dcterms.references | Pernas, S.; Tolaney, S.M. HER2-positive breast cancer: New therapeutic frontiers and overcoming resistance. Ther. Adv. Med. Oncol. 2019, 11. | eng |
| dcterms.references | Büscheck, F.; Fraune, C.; Simon, R.; Kluth, M.; Hube-Magg, C.; Möller-Koop, C.; Shadanpour, N.; Bannenberg, C.; Eichelberg, C.; Höflmayer, D.; et al. Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. Urol. Oncol. Semin. Orig. Investig. 2018, 36, e19–e531. | eng |
| dcterms.references | Li, J.; Li, W.; Huang, K.; Zhang, Y.; Kupfer, G.; Zhao, Q. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: Lessons learned and strategies for moving forward. J. Hematol. Oncol. 2018, 11, 22. | eng |
| dcterms.references | Lamers, C.H.J.; Willemsen, R.A.; Van Elzakker, P.; Van Krimpen, B.A.; Gratama, J.W.; Debets, R. Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: Implications for clinical immunogene therapy of cancer. Cancer Gene Ther. 2006, 13, 503–509. | eng |
| dcterms.references | Holzinger, A.; Abken, H. CAR T cells targeting solid tumors: Carcinoembryonic antigen (CEA) proves to be a safe target. Cancer Immunol. Immunother. 2017, 66, 1505–1507. | eng |
| dcterms.references | Zhang, C.; Wang, Z.; Yang, Z.; Wang, M.; Li, S.; Li, Y.; Zhang, R.; Xiong, Z.; Wei, Z.; Shen, J.; et al. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers. Mol. Ther. 2017, 25, 1248–1258. | eng |
| dcterms.references | Zhang, B.L.; Qin, D.Y.; Mo, Z.M.; Li, Y.; Wei, W.; Wang, Y.S.; Wang, W.; Wei, Y.Q. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Sci. China Life Sci. 2016, 59, 340–348. | eng |
| dcterms.references | Kosti, P.; Maher, J.; Arnold, J.N. Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors. Front. Immunol. 2018, 9, 1104 | eng |
| dcterms.references | Lei, X.; Lei, Y.; Li, J.K.; Du, W.X.; Li, R.G.; Yang, J.; Li, J.; Li, F.; Tan, H.B. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett. 2020, 470, 126–133. | eng |
| dcterms.references | Spill, F.; Reynolds, D.S.; Kamm, R.D.; Zaman, M.H. Impact of the physical microenvironment on tumor progression and metastasis. Curr. Opin. Biotechnol. 2016, 40, 41–48. | eng |
| dcterms.references | Overchuk, M.; Zheng, G. Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics. Biomaterials 2018, 156, 217–237. | eng |
| dcterms.references | Guo, X.; Jiang, H.; Shi, B.; Zhou, M.; Zhang, H.; Shi, Z.; Du, G.; Luo, H.; Wu, X.; Wang, Y.; et al. Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma. Front. Pharmacol. 2018, 9, 1118. | eng |
| dcterms.references | Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. J. Jpn. Soc. Clin. Immunol. 2017, 40, 68–77. | eng |
| dcterms.references | Beatty, G.L.; O’Hara, M. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. Pharmacol. Ther. 2016, 166, 30–39. | eng |
| dcterms.references | Yaguchi, T.; Kawakami, Y. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int. Immunol. 2016, 28, 393–399. | eng |
| dcterms.references | McGowan, E.; Lin, Q.; Ma, G.; Yin, H.; Chen, S.; Lin, Y. PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. Biomed. Pharmacother. 2020, 121, 109625. | eng |
| dcterms.references | Zhang, E.; Gu, J.; Xu, H. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Mol. Cancer 2018, 17, 7. | eng |
| dcterms.references | Xiao, B.F.; Zhang, J.T.; Zhu, Y.G.; Cui, X.R.; Lu, Z.M.; Yu, B.T.; Wu, N. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges. Front. Immunol. 2021, 12, 782775. | eng |
| dcterms.references | Long, L.; Zhang, X.; Chen, F.; Pan, Q.; Phiphatwatchara, P.; Zeng, Y.; Chen, H. The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy. Genes Cancer 2018, 9, 176. | eng |
| dcterms.references | Das, M.; Zhu, C.; Kuchroo, V.K. Tim-3 and its role in regulating anti-tumor immunity. Immunol. Rev. 2017, 276, 97–111. | eng |
| dcterms.references | Moon, E.K.; Wang, L.C.; Dolfi, D.V.; Wilson, C.B.; Ranganathan, R.; Sun, J.; Kapoor, V.; Scholler, J.; Puré, E.; Milone, M.C.; et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin. Cancer Res. 2014, 20, 4262–4273. | eng |
| dcterms.references | Casey, S.C.; Amedei, A.; Aquilano, K.; Azmi, A.S.; Benencia, F.; Bhakta, D.; Bilsland, A.E.; Boosani, C.S.; Chen, S.; Ciriolo, M.R.; et al. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin. Cancer Biol. 2015, 35, S199–S223. | eng |
| dcterms.references | Wang, M.; Zhao, J.; Zhang, L.; Wei, F.; Lian, Y.; Wu, Y.; Gong, Z.; Zhang, S.; Zhou, J.; Cao, K.; et al. Role of tumor microenvironment in tumorigenesis. J. Cancer 2017, 8, 761–773. | eng |
| dcterms.references | Abken, H. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells. Hum. Gene Ther. 2017, 28, 1047–1060. | eng |
| dcterms.references | Hamidi, H.; Ivaska, J. Every step of the way: Integrins in cancer progression and metastasis. Nat. Rev. Cancer 2018, 18, 533–548. | eng |
| dcterms.references | Akbari, P.; Huijbers, E.J.M.; Themeli, M.; Griffioen, A.W.; van Beijnum, J.R. The tumor vasculature an attractive CAR T cell target in solid tumors. Angiogenesis 2019, 22, 473–475. | eng |
| dcterms.references | Newton, R.; Priyadharshini, B.; Turka, L.A. Immunometabolism of regulatory T cells. Nat. Immunol. 2016, 17, 618–625. | eng |
| dcterms.references | Liberti, M.V.; Locasale, J.W. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem. Sci. 2016, 41, 211–218. | eng |
| dcterms.references | Singer, K.; Cheng, W.C.; Kreutz, M.; Ho, P.C.; Siska, P.J. Immunometabolism in cancer at a glance. DMM Dis. Models Mech. 2018, 11, dmm034272 | eng |
| dcterms.references | Marchiq, I.; Pouysségur, J. Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H+ symporters. J. Mol. Med. 2016, 94, 155–171. | eng |
| dcterms.references | Lee, C.F.; Lo, Y.C.; Cheng, C.H.; Furtmüller, G.J.; Oh, B.; Andrade-Oliveira, V.; Thomas, A.G.; Bowman, C.E.; Slusher, B.S.; Wolfgang, M.J.; et al. Preventing Allograft Rejection by Targeting Immune Metabolism. Cell Rep. 2015, 13, 760–770. | eng |
| dcterms.references | Diaz, B.; Yuen, A. The impact of hypoxia in pancreatic cancer invasion and metastasis. Hypoxia 2014, 91, 91–106. | eng |
| dcterms.references | Fraley, S.I.; Wu, P.H.; He, L.; Feng, Y.; Krisnamurthy, R.; Longmore, G.D.; Wirtz, D. Three-dimensional matrix fiber alignment modulates cell migration and MT1-MMP utility by spatially and temporally directing protrusions. Sci. Rep. 2015, 5, 14580. | eng |
| dcterms.references | Hennequart, M.; Pilotte, L.; Cane, S.; Hoffmann, D.; Stroobant, V.; Plaen, E.D.; Eynde, B.J.V.D. Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance. Cancer Immunol. Res. 2017, 5, 695–709. | eng |
| dcterms.references | Yu, C.P.; Song, Y.L.; Zhu, Z.M.; Huang, B.; Xiao, Y.Q.; Luo, D.Y. Targeting TDO in cancer immunotherapy. Med. Oncol. 2017, 34, 73. | eng |
| dcterms.references | Slaney, C.Y.; Kershaw, M.H.; Darcy, P.K. Trafficking of T cells into tumors. Cancer Res. 2014, 74, 7168–7174. | eng |
| dcterms.references | Kitamura, T.; Qian, B.Z.; Pollard, J.W. Immune cell promotion of metastasis. Nat. Rev. Immunol. 2015, 15, 73–86. | eng |
| dcterms.references | Yong, C.S.M.; Dardalhon, V.; Devaud, C.; Taylor, N.; Darcy, P.K.; Kershaw, M.H. CAR T-cell therapy of solid tumors. Immunol. Cell Biol. 2017, 95, 356–363. | eng |
| dcterms.references | Nakagawa, Y.; Negishi, Y.; Shimizu, M.; Takahashi, M.; Ichikawa, M.; Takahashi, H. Effects of extracellular pH and hypoxia on the function and development of antigen-specific cytotoxic T lymphocytes. Immunol Lett. 2015, 167, 72–86. | eng |
| dcterms.references | Van Der Zijpp, Y.J.T.; Poot, A.A.; Feijen, J. ICAM-1 and VCAM-1 expression by endothelial cells grown on fibronectin-coated TCPS and PS. J. Biomed. Mater. Res. A 2003, 65, 51–59. | eng |
| dcterms.references | Stock, S.; Schmitt, M.; Sellner, L. Optimizing manufacturing protocols of chimeric antigen receptor t cells for improved anticancer immunotherapy. Int. J. Mol. Sci. 2019, 20, 6223. | eng |
| dcterms.references | Brown, M.H.; Dustin, M.L. Retraction: Steering CAR T Cells into Solid Tumors. N. Engl. J. Med. 2019, 380, 289–291. | eng |
| dcterms.references | Knochelmann, H.M.; Smith, A.S.; Dwyer, C.J.; Wyatt, M.M.; Mehrotra, S.; Paulos, C.M. CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. Front. Immunol. 2018, 9, 1740. | eng |
| dcterms.references | Ager, A.; Watson, H.A.; Wehenkel, S.C.; Mohammed, R.N. Homing to solid cancers: A vascular checkpoint in adoptive cell therapy using CAR T-cells. Biochem. Soc. Trans. 2016, 44, 377–385. | eng |
| dcterms.references | Chow, M.T.; Luster, A.D. Chemokines in cancer. Cancer Immunol. Res. 2014, 2, 1125–1131. | eng |
| dcterms.references | Waldmann, T.A. Cytokines in cancer immunotherapy. Cold Spring Harb. Perspect. Biol. 2018, 10, a028472. | eng |
| dcterms.references | Kershaw, M.H.; Wang, G.; Westwood, J.A.; Pachynski, R.K.; Tiffany, H.L.; Marincola, F.M.; Wang, E.; Young, H.A.; Murphy, P.M.; Hwu, P. Redirecting Migration of T Cells to Chemokine Secreted from Tumors by Genetic Modification with CXCR2. Hum. Gene Ther. 2002, 13, 1971–1980. | eng |
| dcterms.references | Caruana, I.; Savoldo, B.; Hoyos, V.; Weber, G.; Liu, H.; Kim, E.S.; Ittmann, M.M.; Marchetti, D.; Dotti, G. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat. Med. 2015, 21, 524–529. | eng |
| dcterms.references | EBMT. EBMT Registry. 2023. Available online: https://www.ebmt.org/registry/ebmt-car-t-data-collection-initiative (accessed on 21 December 2023). | eng |
| dcterms.references | Daei Sorkhabi, A.; Mohamed Khosroshahi, L.; Sarkesh, A.; Mardi, A.; Aghebati-Maleki, L.; Baradaran, B. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Front. Immunol. 2023, 14, 1113882. | eng |
| dcterms.references | Freyer, C.W.; Porter, D.L. Advances in CAR T Therapy for Hematologic Malignancies. Pharmacotherapy 2020, 40, 741–755. | eng |
| dcterms.references | Slaney, C.Y.; Von Scheidt, B.; Davenport, A.J.; Beavis, P.A.; Westwood, J.A.; Mardiana, S.; Tscharke, D.C.; Ellis, S.; Prince, H.M.; Trapani, J.A.; et al. Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting. Clin. Cancer Res. 2017, 23, 2478–2490. | eng |
| dcterms.references | Hegde, M.; Grada, Z.; Pignata, A.; Wakefield, A.; Fousek, K.; Bielamowicz, K.; Chow, K.; Brawley, V.; Byrd, T.; Gottschalk, S.; et al. A bispecific chimeric antigen receptor molecule enhances T cell activation through dual immunological synapse formation and offsets antigen escape in glioblastoma. J. Immunother. Cancer 2015, 3, 3. | eng |
| dcterms.references | Fedorov, V.D.; Themeli, M.; Sadelain, M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 2013, 5, 215ra172. | eng |
| dcterms.references | Roybal, K.T.; Rupp, L.J.; Morsut, L.; Walker, W.J.; McNally, K.A.; Park, J.S.; Lim, W.A. Precision Tumor Recognition by T Cells with Combinatorial Antigen-Sensing Circuits. Cell 2016, 164, 770–779. | eng |
| dcterms.references | Han, X.; Wang, Y.; Wei, J.; Han, W. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J. Hematol. Oncol. 2019, 12, 128. | eng |
| dcterms.references | Grada, Z.; Hegde, M.; Byrd, T.; Shaffer, D.R.; Ghazi, A.; Brawley, V.S.; Corder, A.; Schönfeld, K.; Koch, J.; Dotti, G.; et al. TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther. Nucleic. Acids. 2013, 2, E105. | eng |
| dcterms.references | Lanitis, E.; Poussin, M.; Klattenhoff, A.W.; Song, D.; Sandaltzopoulos, R.; June, C.H.; Powell, D.J., Jr. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol. Res. 2013, 1, 43–53. | eng |
| dcterms.references | Kondo, T.; Ando, M.; Nagai, N.; Tomisato, W.; Srirat, T.; Liu, B.; Mise-Omata, S.; Ikeda, M.; Chikuma, S.; Nishimasu, H.; et al. The NOTCH–FOXM1 axis plays a key role in mitochondrial biogenesis in the induction of human stem cell memory–like CAR-T cells. Cancer Res. 2020, 80, 471–483. | eng |
| dcterms.references | Roybal, K.T.; Williams, J.Z.; Morsut, L.; Rupp, L.J.; Kolinko, I.; Choe, J.H.; Walker, W.J.; McNally, K.A.; Lim, W.A. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell 2016, 167, 419–432.e16. | eng |
| dcterms.references | Wang, W.; Jiang, J.; Wu, C. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects. Cancer Lett. 2020, 472, 175–180 | eng |
| dcterms.references | Zhang, J.; Basher, F.; Wu, J.D. NKG2D ligands in tumor immunity: Two sides of a coin. Front. Immunol. 2015, 6, 97. | eng |
| dcterms.references | Liu, D. CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: A new era of cancer therapy. J. Hematol. Oncol. 2019, 12, 113. | eng |
| dcterms.references | Burger, M.C.; Zhang, C.; Harter, P.N.; Romanski, A.; Strassheimer, F.; Tonn, T.; Steinbach, J.P. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy. Front. Immunol. 2019, 10, 2683. | eng |
| dcterms.references | Sentman, C.L.; Meehan, K.R. NKG2D CARs as cell therapy for cancer. Cancer J. 2014, 20, 156–159. | eng |
| dcterms.references | Richardson, N.H.; Luttrell, J.B.; Bryant, J.S.; Chamberlain, D.; Khawaja, S.; Neeli, I.; Radic, M. Tuning the performance of CAR T cell immunotherapies. BMC Biotechnol. 2019, 19, 84. | eng |
| dcterms.references | Rodgers, D.T.; Mazagova, M.; Hampton, E.N.; Cao, Y.; Ramadoss, N.S.; Hardy, I.R.; Schulman, A.; Du, J.; Wang, F.; Singer, O.; et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc. Natl. Acad. Sci. USA 2016, 113, E459–E468. | eng |
| dcterms.references | Jones, B.S.; Lamb, L.S.; Goldman, F.; Di Stasi, A. Improving the safety of cell therapy products by suicide gene transfer. Front. Pharmacol. 2014, 5, 254. | eng |
| dcterms.references | Charrot, S.; Hallam, S. CAR-T cells: Future perspectives. Hemasphere 2019, 3, e188. | eng |
| dcterms.references | Stavrou, M.; Philip, B.; Traynor-White, C.; Davis, C.G.; Onuoha, S.; Cordoba, S.; Thomas, S.; Pule, M. A Rapamycin-Activated Caspase 9-Based Suicide Gene. Mol. Ther. 2018, 26, 1266–1276. | eng |
| dcterms.references | Wang, X.; Ping, F.F.; Bakht, S.; Ling, J.; Hassan, W. Immunometabolism features of metabolic deregulation and cancer. J. Cell. Mol. Med. 2019, 23, 694–701. | eng |
| dcterms.references | Van Der Stegen, S.J.C.; Hamieh, M.; Sadelain, M. The pharmacology of second-generation chimeric antigen receptors. Nat. Rev. Drug Discov. 2015, 14, 499–509. | eng |
| dcterms.references | Liu, X.; Ranganathan, R.; Jiang, S.; Fang, C.; Sun, J.; Kim, S.; Newick, K.; Lo, A.; June, C.H.; Zhao, Y.; et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016, 76, 1578–1590. | eng |
| dcterms.references | Jafarzadeh, L.; Masoumi, E.; Fallah-Mehrjardi, K.; Mirzaei, H.R.; Hadjati, J. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward. Front. Immunol. 2020, 11, 702. | eng |
| dcterms.references | Arndt, C.; Feldmann, A.; Koristka, S.; Schäfer, M.; Bergmann, R.; Mitwasi, N.; Berndt, N.; Bachmann, D.; Kegler, A.; Schmitz, M.; et al. A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR. Oncoimmunology 2019, 8, 1659095. | eng |
| dcterms.references | Cho, J.H.; Collins, J.J.; Wong, W.W. Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses. Cell 2018, 173, 1426–1438.e11. | eng |
| dcterms.references | Von Scheidt, B.; Wang, M.; Oliver, A.J.; Chan, J.D.; Jana, M.K.; Ali, A.I.; Clow, F.; Fraser, J.D.; Quinn, K.M.; Darcy, P.K.; et al. Enterotoxins Can Support CAR T Cells against Solid Tumors. Proc. Natl. Acad. Sci. USA 2019, 116, 25229–25235. | eng |
| dcterms.references | Yeku, O.O.; Purdon, T.J.; Koneru, M.; Spriggs, D.; Brentjens, R.J. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci. Rep. 2017, 7, 10541. | eng |
| dcterms.references | Land, C.A.; Musich, P.R.; Haydar, D.; Krenciute, G.; Xie, Q. Chimeric antigen receptor T-cell therapy in glioblastoma: Charging the T cells to fight. J. Transl. Med. 2020, 18, 428. | eng |
| dcterms.references | Hoyos, V.; Savoldo, B.; Quintarelli, C.; Mahendravada, A.; Zhang, M.; Vera, J.; Heslop, H.E.; Rooney, C.M.; Brenner, M.K.; Dotti, G. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010, 24, 1160–1170. | eng |
| dcterms.references | Hu, B.; Ren, J.; Luo, Y.; Keith, B.; Young, R.M.; Scholler, J.; Zhao, Y.; June, C.H. Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18. Cell Rep. 2017, 20, 3025–3033. | eng |
| dcterms.references | Singh, H.; Figliola, M.J.; Dawson, M.J.; Huls, H.; Olivares, S.; Switzer, K.; Mi, T.; Maiti, S.; Kebriaei, P.; Lee, D.A.; et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 2011, 71, 3516–3527. | eng |
| dcterms.references | Koneru, M.; O’Cearbhaill, R.; Pendharkar, S.; Spriggs, D.R.; Brentjens, R.J. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer. J. Transl. Med. 2015, 13, 102. | eng |
| dcterms.references | Ansell, S.M.; Corradini, P. CAR T-cells: Driving in the fast lane. HemaSphere 2019, 3, e209. | eng |
| dcterms.references | Khawar, I.A.; Kim, J.H.; Kuh, H.J. Improving drug delivery to solid tumors: Priming the tumor microenvironment. J. Control. Release 2015, 201, 78–89. | eng |
| dcterms.references | Benitez, J.C.; Remon, J.; Besse, B. Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy. Clin. Cancer Res. 2020, 26, 5068–5077. | eng |
| dcterms.references | Cherkassky, L.; Morello, A.; Villena-Vargas, J.; Feng, Y.; Dimitrov, D.S.; Jones, D.R.; Sadelain, M.; Adusumilli, P.S. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Investig. 2016, 126, 3130–3144. | eng |
| dcterms.references | Nicholas, N.S.; Apollonio, B.; Ramsay, A.G. Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. Biochim. Et Biophys. Acta—Mol. Cell Res. 2016, 1863, 471–482. | eng |
| dcterms.references | Shi, X.; Zhang, D.; Li, F.; Zhang, Z.; Wang, S.; Xuan, Y.; Ping, Y.; Zhang, Y. Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity. J. Hematol. Oncol. 2019, 12, 127. | eng |
| dcterms.references | Ureña-Bailén, G.; Lamsfus-Calle, A.; Daniel-Moreno, A.; Raju, J.; Schlegel, P.; Seitz, C.; Atar, D.; Antony, J.S.; Handgretinger, R.; Mezger, M. CRISPR/Cas9 technology: Towards a new generation of improved CAR-T cells for anticancer therapies. Brief. Funct. Genom. 2020, 19, 191–200. | eng |
| dcterms.references | Wei, W.; Chen, Z.N.; Wang, K. CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. Int. J. Mol. Sci. 2023, 24, 12317. | eng |
| dcterms.references | Pesch, T.; Bonati, L.; Kelton, W.; Parola, C.; Ehling, R.A.; Csepregi, L.; Kitamura, D.; Reddy, S.T. Molecular Design, Optimization, and Genomic Integration of Chimeric B Cell Receptors in Murine B Cells. Front Immunol. 2019, 10, 2630. | eng |
| dcterms.references | Milano, G. Resistance to immunotherapy: Clouds in a bright sky. Investig. New Drugs 2017, 35, 649–654. | eng |
| dcterms.references | Abid, M.B.; Shah, N.N.; Maatman, T.C.; Hari, P.N. Gut microbiome and CAR-T therapy. Exp. Hematol. Oncol. 2019, 8, 31. | eng |
| dcterms.references | Netea-Maier, R.T.; Smit, J.W.A.; Netea, M.G. Metabolic changes in tumor cells and tumor-associated macrophages: A mutual relationship. Cancer Lett. 2018, 413, 102–109. | eng |
| dcterms.references | Doedens, A.L.; Phan, A.T.; Stradner, M.H.; Fujimoto, J.K.; Nguyen, J.V.; Yang, E.; Johnson, R.S.; Goldrath, A.W. Hypoxia-inducible factors enhance the effector responses of CD8 + T cells to persistent antigen. Nat. Immunol. 2013, 14, 1173–1182. | eng |
| dcterms.references | Tyrakis, P.A.; Palazon, A.; Macias, D.; Lee, K.L.; Phan, A.T.; Veliça, P.; You, J.; Chia, G.S.; Sim, J.; Doedens, A.; et al. S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate. Nature 2016, 540, 236–241. | eng |
| dcterms.references | Sukumar, M.; Liu, J.; Ji, Y.; Subramanian, M.; Crompton, J.G.; Yu, Z.; Roychoudhuri, R.; Palmer, D.C.; Muranski, P.; Karoly, E.D.; et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J. Clin. Investig. 2013, 123, 4479–4488. | eng |
| dcterms.references | Chambers, A.M.; Lupo, K.B.; Matosevic, S. Tumor microenvironment-induced immunometabolic reprogramming of natural killer cells. Front. Immunol. 2018, 9, 2517. | eng |
| dcterms.references | Ligtenberg, M.A.; Mougiakakos, D.; Mukhopadhyay, M.; Witt, K.; Lladser, A.; Chmielewski, M.; Riet, T.; Abken, H.; Kiessling, R. Coexpressed Catalase Protects Chimeric Antigen Receptor–Redirected T Cells as well as Bystander Cells from Oxidative Stress–Induced Loss of Antitumor Activity. J. Immunol. 2016, 196, 759–766. | eng |
| dcterms.references | Michot, J.M.; Annereau, M.; Danu, A.; Legoupil, C.; Bertin, L.; Chahine, C.; Achab, N.; Antosikova, A.; Cerutti, A.; Rossignol, J.; et al. High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma, a phase II result. Eur. J. Haematol. 2020, 104, 281–290. | eng |
| dcterms.references | Ninomiya, S.; Narala, N.; Huye, L.; Yagyu, S.; Savoldo, B.; Dotti, G.; Heslop, H.E.; Brenner, M.K.; Rooney, C.M.; Ramos, C.A. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 2015, 125, 3905–3916. | eng |
| dcterms.references | Kloss, C.C.; Lee, J.; Zhang, A.; Chen, F.; Melenhorst, J.J.; Lacey, S.F.; Maus, M.V.; Fraietta, J.A.; Zhao, Y.; June, C.H. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Mol. Ther. 2018, 26, 1855–1866. | eng |
| dcterms.references | Crompton, J.G.; Sukumar, M.; Roychoudhuri, R.; Clever, D.; Gros, A.; Eil, R.L.; Tran, E.; Hanada, K.I.; Yu, Z.; Palmer, D.C.; et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 2015, 75, 296–305. | eng |
| dcterms.references | De Marco, R.C.; Monzo, H.J.; Ojala, P.M. CAR T Cell Therapy: A Versatile Living Drug. Int. J. Mol. Sci. 2023, 24, 6300. | eng |
| dcterms.references | Wang, X.; Scarfò, I.; Schmidts, A.; Toner, M.; Maus, M.V.; Irimia, D. Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays. Adv. Sci. 2019, 6, 1901829. | eng |
| dcterms.references | Klemm, F.; Joyce, J.A. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015, 25, 198–213. | eng |
| dcterms.references | Hyrenius-Wittsten, A.; Roybal, K.T. Paving New Roads for CARs. Trends Cancer 2019, 25, 583–592. | eng |
| dcterms.references | Harlin, H.; Meng, Y.; Peterson, A.C.; Zha, Y.; Tretiakova, M.; Slingluff, C.; McKee, M.; Gajewski, T.F. Chemokine expression in melanoma metastases associated with CD8 + T-CeII recruitment. Cancer Res. 2009, 69, 3077–3085. | eng |
| dcterms.references | Craddock, J.A.; Lu, A.; Bear, A.; Pule, M.; Brenner, M.K.; Rooney, C.M.; Foster, A.E. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 2010, 33, 780–788. | eng |
| dcterms.references | Spear, P.; Barber, A.; Sentman, C.L. Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology 2013, 2, e23564. | eng |
| dcterms.references | Brown, C.E.; Vishwanath, R.P.; Aguilar, B.; Starr, R.; Najbauer, J.; Aboody, K.S.; Jensen, M.C. Tumor-Derived Chemokine MCP-1/CCL2 Is Sufficient for Mediating Tumor Tropism of Adoptively Transferred T Cells. J. Immunol. 2007, 179, 3332–3341. | eng |
| dcterms.references | Granziero, L.; Krajewski, S.; Farness, P.; Yuan, L.; Courtney, M.K.; Jackson, M.R.; Peterson, P.A.; Vitiello, A. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur. J. Immunol. 1999, 29, 1127–1138. | eng |
| dcterms.references | Adusumilli, P.S.; Cherkassky, L.; Villena-Vargas, J.; Colovos, C.; Servais, E.; Plotkin, J.; Jones, D.R.; Sadelain, M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 2014, 6, 261ra151. | eng |
| dcterms.references | Yeku, O.O.; Brentjens, R.J. Armored CAR T-cells: Utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem. Soc. Trans. 2016, 40, 412–418. | eng |
| dcterms.references | Feig, C.; Jones, J.O.; Kraman, M.; Wells, R.J.B.; Deonarine, A.; Chan, D.S.; Connell, C.M.; Roberts, E.W.; Zhao, Q.; Caballero, O.L.; et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA 2013, 110, 20212–20217. | eng |
| dcterms.references | Ma, S.; Li, X.; Wang, X.; Cheng, L.; Li, Z.; Zhang, C.; Ye, Z.; Qian, Q. Current progress in car-t cell therapy for solid tumors. Int. J. Biol. Sci. 2019, 15, 2548–2560. | eng |
| dcterms.references | Kandalaft, L.E.; Facciabene, A.; Buckanovich, R.J.; Coukos, G. Endothelin B receptor, a new target in cancer immune therapy. Clin. Cancer Res. 2009, 15, 4521–4528. | eng |
| dcterms.references | Newick, K.; O’brien, S.; Sun, J.; Kapoor, V.; Maceyko, S.; Lo, A.; Pure, E.; Moon, E.; Albelda, S.M. Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase a localization. Cancer Immunol. Res. 2016, 4, 541–551. | eng |
| dcterms.references | Guedan, S.; Alemany, R. CAR-T cells and oncolytic viruses: Joining forces to overcome the solid tumor challenge. Front. Immunol. 2018, 9, 2460. | eng |
| dcterms.references | Aalipour, A.; Le Boeuf, F.; Tang, M.; Murty, S.; Simonetta, F.; Lozano, A.X.; Shaffer, T.M.; Bell, J.C.; Gambhir, S.S. Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy. Mol. Ther. Oncolytics 2020, 17, 232–240. | eng |
| dcterms.references | Shi, T.; Song, X.; Wang, Y.; Liu, F.; Wei, J. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. Front. Immunol. 2020, 11, 683. | eng |
| dcterms.references | Heo, J.; Reid, T.; Ruo, L.; Breitbach, C.J.; Rose, S.; Bloomston, M.; Cho, M.; Lim, H.Y.; Chung, H.C.; Kim, C.W.; et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 2013, 19, 329–336. | eng |
| dcterms.references | Nishio, N.; Diaconu, I.; Liu, H.; Cerullo, V.; Caruana, I.; Hoyos, V.; Bouchier-Hayes, L.; Savoldo, B.; Dotti, G. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 2014, 74, 5195–5205. | eng |
| dcterms.references | Tsai, A.K.; Davila, E. Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors. OncoImmunology 2016, 5, e1122158. | eng |
| dcterms.references | Parente-Pereira, A.C.; Burnet, J.; Ellison, D.; Foster, J.; Davies, D.M.; Van der Stegen, S.; Burbridge, S.; Chiapero-Stanke, L.; Wilkie, S.; Mather, S.; et al. Trafficking of CAR-Engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J. Clin. Immunol. 2011, 31, 710–718. | eng |
| dcterms.references | Katz, S.C.; Burga, R.A.; McCormack, E.; Wang, L.J.; Mooring, W.; Point, G.R.; Khare, P.D.; Thorn, M.; Ma, Q.; Stainken, B.F.; et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin. Cancer Res. 2015, 21, 3149–3159. | eng |
| dcterms.references | Priceman, S.J.; Tilakawardane, D.; Jeang, B.; Aguilar, B.; Murad, J.P.; Park, A.K.; Chang, W.C.; Ostberg, J.R.; Neman, J.; Jandial, R.; et al. Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2 + breast cancer metastasis to the brain. Clin. Cancer Res. 2018, 24, 95–105. | eng |
| dcterms.references | Brown, C.E.; Alizadeh, D.; Starr, R.; Weng, L.; Wagner, J.R.; Naranjo, A.; Ostberg, J.R.; Blanchard, M.S.; Kilpatrick, J.; Simpson, J.; et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N. Engl. J. Med. 2016, 375, 2561–2569. | eng |
| dcterms.references | Coon, M.E.; Stephan, S.B.; Gupta, V.; Kealey, C.P.; Stephan, M.T. Nitinol thin films functionalized with CAR-T cells for the treatment of solid tumours. Nat. Biomed. Eng. 2020, 4, 195–206. | eng |
| dcterms.references | Beyer, I.; Li, Z.; Persson, J.; Liu, Y.; Van Rensburg, R.; Yumul, R.; Zhang, X.-B.; Hung, M.-C.; Lieber, A. Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. Mol. Ther. 2011, 19, 479–489. | eng |
| dcterms.references | Chinnasamy, D.; Yu, Z.; Theoret, M.R.; Zhao, Y.; Shrimali, R.R.K.; Morgan, R.A.; Feldman, S.A.; Restifo, N.P.; Rosenberg, S.A. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Investig. 2010, 120, 3953–3968. | eng |
| dcterms.references | Yasuda, S.; Sho, M.; Yamato, I.; Yoshiji, H.; Wakatsuki, K.; Nishiwada, S.; Yagita, H.; Nakajima, Y. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin. Exp. Immunol. 2013, 172, 500–506. | eng |
| dcterms.references | Whilding, L.M.; Parente-Pereira, A.C.; Zabinski, T.; Davies, D.M.; Petrovic, R.M.; Kao, Y.V.; Saxena, S.A.; Romain, A.; Costa-Guerra, J.A.; Violette, S.; et al. Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells. Mol. Ther. 2017, 25, 259–273. | eng |
| dcterms.references | Shrimali, R.K.; Yu, Z.; Theoret, M.R.; Chinnasamy, D.; Restifo, N.P.; Rosenberg, S.A. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010, 70, 6171–6180. | eng |
| dcterms.references | Schuberth, P.C.; Hagedorn, C.; Jensen, S.M.; Gulati, P.; van den Broek, M.; Mischo, A.; Soltermann, A.; Jüngel, A.; Belaunzaran, O.M.; Stahel, R.; et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J. Transl. Med. 2013, 11, 187. | eng |
| dcterms.references | Uscanga-Palomeque, A.C.; Chávez-Escamilla, A.K.; Alvizo-Báez, C.A.; Saavedra-Alonso, S.; Terrazas-Armendáriz, L.D.; Tamez-Guerra, R.S.; Rodríguez-Padilla, C.; Alcocer-González, J.M. CAR-T Cell Therapy: From the Shop to Cancer Therapy. Int. J. Mol. Sci. 2023, 24, 15688. | eng |
| dcterms.references | Aghajanian, H.; Rurik, J.G.; Epstein, J.A. CAR-based therapies: Opportunities for immuno-medicine beyond cancer. Nat. Metab. 2022, 4, 163–169. | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion |